Latest news with #DESTINYBreast09

Medscape

Conference MDAngle: ASCO 2025 Metastatic Breast Cancer

Preconference Considerations ASCO 2025: Previewing Updates in Metastatic Breast Cancer Dr McArthur is eager to attend the 2025 ASCO Annual Meeting, where key breast cancer studies will be presented. Highlights include DESTINY-Breast09 and ASCENT-04, showing promising results for antibody-drug conjugates in HER2-positive and triple-negative breast cancer. Additionally, EMBER-3, INAVO120, and VERITAC-2 offer new insights into targeted therapies for HR-positive disease. Dr McArthur sees these findings as advancing precision medicine. Quick Clinical Takeaways Coming soon: Dr McArthur highlights new data and progress regarding metastatic breast cancer immediately following ASCO. How Will My Patients Benefit? Coming soon: Reflections from Dr McArthur on how new data from ASCO will affect her patients with metastatic breast cancer. Image 1: Heather McArthur, MD, MPH